Cargando…
Real-world data on T-DM1 efficacy – results of a single-center retrospective study of HER2-positive breast cancer patients
T-DM1 is an antibody drug conjugate that combines trastuzumab with emtansine via a stable thioether linker. In two phase III clinical trials, EMILIA and TH3RESA, T-DM1 was shown to be effective in HER2-positive metastatic breast cancer patients who had progressed to taxanes and trastuzumab. We have...
Autores principales: | Hardy-Werbin, Max, Quiroga, Vanesa, Cirauqui, Beatriz, Romeo, Margarita, Felip, Eudald, Teruel, Iris, Garcia, Juan Jose, Erasun, Carlos, España, Sofia, Cucurull, Marc, Montprade, Elisabeth, Pardo, Juan Carlos, Carballo, Dania, Velarde, Jose Maria, Margeli, Mireia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6726763/ https://www.ncbi.nlm.nih.gov/pubmed/31484985 http://dx.doi.org/10.1038/s41598-019-49251-5 |
Ejemplares similares
-
Conventional and digital Ki67 evaluation and their correlation with molecular prognosis and morphological parameters in luminal breast cancer
por: Pons, Laura, et al.
Publicado: (2022) -
Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer
por: Ferrando-Díez, Angelica, et al.
Publicado: (2022) -
Role of ctDNA in Breast Cancer
por: Sant, Marta, et al.
Publicado: (2022) -
Pre- and Post-Neoadjuvant Clinicopathological Parameters Can Help in the Prognosis and the Prediction of Response in HER2+ and Triple Negative Breast Cancer
por: Pons, Laura, et al.
Publicado: (2023) -
Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer
por: Romeo, Margarita, et al.
Publicado: (2018)